LDL-apheresis is an extracorporeal technique which removes all apo B10
0-containing lipoproteins (VLDL, LDL, Lp(a)) from plasma, in patients
with homozygous, and double heterozygous, familial hypercholesterolemi
a (FH). One of the most significant technical characteristics of LDL-a
pheresis is the selectivity in the removal of atherogenic lipoproteins
, namely LDLs, which has been improved in the most recently developed
techniques. The oldest system for therapeutic plasmapheresis in the tr
eatment of severe hyperlipoproteinemias, is plasma-exchange, where all
plasma components are unselectively removed. More recently, the syste
ms (dextransulphate cellulose LDL-apheresis [DSC/LDL-A], heparin induc
ed LDL precipitation-apheresis [HELP/LDL-A] immunoadsorption LDL-apher
esis [IMA/LDL-A], direct adsorption of lipids [DALI]) have permitted a
selective removal of LDL and of other apo B100-containing lipoprotein
s. The higher selectivity, thus the higher efficacy and safety, has al
so allowed the treatment of high risk patients with severe cardiovascu
lar conditions, and pediatric patients. Therefore, it is currently pos
sible to begin treatment with LDL-apheresis, even at a very early age.
The most recent system for LDL-apheresis (DALI: Direct Adsorption of
Lipids) even permits the removal of LDL from whole blood, without prev
ious cell/plasma separation. This system is promising for further prog
ress in the technology related to LDL-apheresis.